Items where authors include "Angiolillo, D.J."

Article

Ajjan, R.A., Kietsiriroje, N., Badimon, L. et al. (6 more authors) (2021) Antithrombotic therapy in diabetes: which, when, and for how long? European Heart Journal, 42 (23). pp. 2235-2259. ISSN 0195-668X

Magnani, G., Ardissino, D., Im, K. et al. (15 more authors) (2021) Predictors, type, and impact of bleeding on the net clinical benefit of long‐term Ticagrelor in stable patients with prior myocardial infarction. Journal of the American Heart Association, 10 (4). e017008.

Storey, R.F. orcid.org/0000-0002-6677-6229, Gurbel, P.A., ten Berg, J. et al. (14 more authors) (2020) Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. European Heart Journal, 41 (33). pp. 3132-3140. ISSN 0195-668X

Franchi, F., James, S.K., Ghukasyan Lakic, T. et al. (10 more authors) (2019) Impact of diabetes Mellitus and Chronic Kidney Disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: Insights from the PLATO trial. Journal of the American Heart Association, 8 (6). e011139. ISSN 2047-9980

Åstrand, M. orcid.org/0000-0003-2053-3413, Amilon, C., Röshammar, D. et al. (6 more authors) (2019) Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. British Journal of Clinical Pharmacology, 85 (2). pp. 413-421. ISSN 0306-5251

Lowenstern, A., Storey, R.F. orcid.org/0000-0002-6677-6229, Neely, M. et al. (12 more authors) (2017) Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 44 (2). pp. 145-153. ISSN 0929-5305

Storey, R.F. orcid.org/0000-0002-6677-6229, Angiolillo, D.J., Bonaca, M.P. et al. (12 more authors) (2016) Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. Journal of the American College of Cardiology, 67 (10). pp. 1145-1154. ISSN 0735-1097

Proceedings Paper

Storey, R.F. orcid.org/0000-0002-6677-6229, Gurbel, P.A., James, S. et al. (12 more authors) (2019) 2349: Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients. In: EUROPEAN HEART JOURNAL. ESC Congress 2019 together with World Congress of Cardiology, 31 Aug - 04 Sep 2019, Paris, France. Oxford University Press , p. 1355.